Efavirenz

OCT3/4 (POU5F1) is a transcription factor that is expressed in stem cells and germ cells. Its expression is required to sustain cell self-renewal of undifferentiated stem cells.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

General description Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards Application

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI).

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Biochem/physiol Actions Efavirenz is a nonnucleoside reverse transcriptase inhibitor (NNRTI). Efavirenz is an anti-HIV drug, commonly used in combination therapy for AIDs treatment.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

An non-nucleoside reverse transcriptase inhibitor that prevents RNA plus-strand initiation (IC₅₀ = 17 nM) also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing.

An non-nucleoside reverse transcriptase inhibitor that prevents RNA plus-strand initiation (IC₅₀ = 17 nM) also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing.

An non-nucleoside reverse transcriptase inhibitor that prevents RNA plus-strand initiation (IC₅₀ = 17 nM) also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing.

An non-nucleoside reverse transcriptase inhibitor that prevents RNA plus-strand initiation (IC₅₀ = 17 nM) also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing.